11β-HSD1 inhibitors for the treatment of type 2 diabetes and cardiovascular disease

Drugs

Volumn 73, Issue 13, 2013, Pages 1385-1393

  Anderson, Anna ^a   Walker, Brian R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; 3 CHLORO 2 METHYL N [4 [2 (4 METHYL 1 PIPERAZINYL) 2 OXOETHYL] 2 THIAZOLYL]BENZENESULFONAMIDE; CARBENOXOLONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; METFORMIN; MK 0736; MK 0916; OXIDOREDUCTASE INHIBITOR; PF 00915275; PREDNISOLONE; PREDNISONE; UNCLASSIFIED DRUG;

ACNE; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ATHEROMA; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COGNITION; COGNITIVE DEFECT; DRUG TOLERABILITY; DYSLIPIDEMIA; ENZYME INHIBITION; FAT MASS; FOOD INTAKE; GLYCEMIC CONTROL; GLYCOGENOLYSIS; HIRSUTISM; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERGLUCAGONEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INNATE IMMUNITY; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MENSTRUATION DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHARMACOPHORE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULAR LESION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; IMMUNITY, INNATE; METABOLIC SYNDROME X; MOLECULAR TARGETED THERAPY;

EID: 84884626275     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0112-5     Document Type: Article

References (68)

1. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764-70.
2. Stewart PM, Krozowski ZS. 11 Beta-hydroxysteroid dehydrogenase. Vitam Horm. 1999;57:249-324.
3. Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology. 2001;142:1371-6.
4. Tomlinson JW, Walker EA, Bujalska IJ, et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev. 2004;25:831-66.
5. Andrew R, Westerbacka J, Wahren J, Yki-Jarvinen H, Walker BR. The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes. 2005;54:1364-70.
6. Stimson RH, Andersson J, Andrew R, et al. Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans. Diabetes. 2009;58:46-53.
7. Basu R, Singh RJ, Basu A, et al. Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-beta hydroxysteroid dehydrogenase (11 beta-HSD) type 1 pathway. Diabetes. 2004;53:2051-9.
8. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007;157:545-59.
9. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166-70.
10. Masuzaki H, Yamamoto H, Kenyon CJ, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest. 2003;112:83-90.
11. Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA. 2004;101:7088-93.
12. Rask E, Olsson T, Soderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab. 2001;86:1418-21.
13. Rask E, Walker BR, Soderberg S, et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab. 2002;87:3330-6.
14. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisone→cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab. 1999;84:1022-7.
15. Livingstone DE, Jones GC, Smith K, et al. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology. 2000;141:560-3.
16. Jamieson PM, Chapman KE, Edwards CR, Seckl JR. 11 beta-hydroxysteroid dehydrogenase is an exclusive 11 beta-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology. 1995;136:4754-61.
17. Stimson RH, Andrew R, McAvoy NC, Tripathi D, Hayes PC, Walker BR. Increased whole-body and sustained liver cortisol regeneration by 11 beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes. 2011;60:720-5.
18. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA. 1997;94:14924-9.
19. Basu R, Basu A, Grudzien M, et al. Liver is the site of splanchnic cortisol production in obese nondiabetic humans. Diabetes 2009;58:39-45
20. Lavery GG, Zielinska AE, Gathercole LL, et al. Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11 beta-hydroxysteroid dehydrogenase type 1. Endocrinology. 2012;153:3236-48.
21. Webster SP, Pallin TD. 11 beta-hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents. Expert Opin Ther Patents. 2007;17:1407-22.
22. Li RS, Nakagawa Y, Nakanishi T, Fujisawa Y, Ohzeki T. Different responsiveness in body weight and hepatic 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 1 mrna to 11beta-HSD inhibition by glycyrrhetinic acid treatment in obese and lean zucker rats. Metabolism. 2004;53:600-6.
23. Andrews RC, Rooyackers O, Walker BR. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:285-91.
24. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CR. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab. 1995;80:3155-9.
25. Sandeep TC, Yau JLW, MacLullich AMJ, et al. 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci USA. 2004;101:6734-9.
26. Sandeep TC, Andrew R, Homer NZM, Andrews RC, Smith K, Walker BR. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11 beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes. 2005;54:872-9.
27. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet. 1997;349:1210-3.
28. Alberts P, Engblom L, Edling N, et al. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia. 2002;45:1528-32.
29. Jones RM, Thurston DE, Rotella D, Guccione S, Martinez A. New therapeutic strategies for type 2 diabetes: small molecule approaches. Royal Society of Chemistry Publishing; 2012.
30. St. Jean DJ, Yuan C, Bercot EA, et al. 2-(S)-Phenethylaminothiazolones as potent, orally efficacious inhibitors of 11β-hydroxysteriod dehydrogenase type 1. J Med Chem. 2007;50:429-32.
31. Sundbom M, Kaiser C, Bjorkstrand E, et al. Inhibition of 11betaHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice. BMC Pharmacol. 2008;8:3.
32. Courtney R, Stewart PM, Toh M, Ndongo MN, Calle RA, Hirshberg B. Modulation of 11 beta-hydroxysteroid dehydrogenase (11 beta HSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11 beta HSD1 inhibitor. J Clin Endocrinol Metab. 2008;93:550-6.
33. Andrew R, Smith K, Jones GC, Walker BR. Distinguishing the activities of 11 beta-hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol. J Clin Endocrinol Metab. 2002;87:277-85.
34. A study to evaluate PF-00915275 in subjects with type 2 diabetes mellitus for 4-weeks [ClinicalTrials.gov identifier NCT00427401]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov (Accessed 7 Feb 2013).
35. Hawkins M, Hunter D, Kishore P, et al. INCB013739, a selective inhibitor of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta HSD1), improves insulin sensitivity and lowers plasma cholesterol over 28 days in patients with type 2 diabetes mellitus. Diabetes. 2008;57:A99-100.
36. Rosenstock J, Banarer S, Fonseca VA, et al. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care. 2010;33:1516-22.
37. Feig PU, Shah S, Hermanowski-Vosatka A, et al. Effects of an 11 beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab. 2011;13:498-504.
38. Morton NM, Holmes MC, Fievet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11 beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem. 2001;276:41293-300.
39. Berthiaume M, Laplante M, Festuccia WT, et al. 11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues. Am J Physiol Endocrinol Metab. 2007;293:E1045-52.
40. Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11 beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med. 2005;202:517-27.
41. Schwartz SL, Rendell M, Ahmann AJ, Thomas A, Arauz-Pacheco CJ, Welles BR. Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus. Clin Ther. 2008;30:1081-8.
42. Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol. 2008;197:189-204.
43. Bruce CR, Anderson MJ, Carey AL, et al. Muscle oxidative capacity is a better predictor of insulin sensitivity than lipid status. J Clin Endocrinol Metab. 2003;88:5444-51.
44. Shah S, Hermanowski-Vosatka A, Gibson K, et al. Efficacy and safety of the selective 11beta-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. J Am Soc Hypertens. 2011;5:166-76.
45. Morton NM, Paterson JM, Masuzaki H, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes. 2004;53:931-8.
46. Wang L, Liu J, Zhang A, et al. BVT.2733, a selective 11beta- hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice. PLoS One. 2012;7:e40056.
47. Alberts P, Nilsson C, Selen G, et al. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003;144:4755-62.
48. Iqbal J, Macdonald LJ, Low L, et al. Contribution of endogenous glucocorticoids and their intravascular metabolism by 11β-HSDs to postangioplasty neointimal proliferation in mice. Endocrinology. 2012;153:5896-905.
49. Merck. Dose-ranging study to evaluate the effectiveness and tolerability of MK0736 in patients with type 2 diabetes mellitus (T2DM) and hypertension [ClinicalTrials.gov identifier NCT00806585]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov (Accessed 7 Feb 2013).
50. Hadoke PW, Iqbal J, Walker BR. Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br J Pharmacol. 2009;156:689-712.
51. Thieringer R, Le Grand CB, Carbin L, et al. 11 beta-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J Immunol. 2001;167:30-5.
52. Walker BR, Yau JL, Brett LP, et al. 11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle and heart: implications for cardiovascular responses to glucocorticoids. Endocrinology. 1991;129:3305-12.
53. Nuotio-Antar AM, Hachey DL, Hasty AH. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Am J Physiol Endocrinol Metab. 2007;293:18.
54. Lloyd DJ, Helmering J, Cordover D, et al. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis. Diabetes Obes Metab. 2009;11:688-99.
55. Garcia RA, Search DJ, Lupisella JA, et al. 11beta-hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE(-)/(-) mice. PLoS One. 2013;8:e53192.
56. Kipari T, Hadoke PW, Iqbal J, et al. 11beta-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis. FASEB J. 2013;27:1519-31.
57. Atalar F, Vural B, Ciftci C, et al. 11beta-hydroxysteroid dehydrogenase type 1 gene expression is increased in ascending aorta tissue of metabolic syndrome patients with coronary artery disease. Genet Mol Res. 2012;11:3122-32.
58. Small GR, Hadoke PWF, Sharif I, et al. Preventing local regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 enhances angiogenesis. Proc Natl Acad Sci USA. 2005;102:12165-70.
59. McSweeney SJ, Hadoke PWF, Kozak AM, et al. Improved heart function follows enhanced inflammatory cell recruitment and angiogenesis in 11βHSD1-deficient mice post-MI. Cardiovasc Res. 2010;88:159-67.
60. Labrie F, Bélanger A, Cusan L, Gomez J-L, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab. 1997;82:2396-402.
61. Harno E, White A. Will treating diabetes with 11β-HSD1 inhibitors affect the HPA axis? Trends Endocrinol Metab. 2010;21:619-27.
62. Carter RN, Paterson JM, Tworowska U, et al. Hypothalamic-pituitary- adrenal axis abnormalities in response to deletion of 11 beta-HSD1 is strain-dependent. J Neuroendocrinol. 2009;21:879-87.
63. Coutinho AE, Brown JK, Yang F, et al. Mast cells express 11β-hydroxysteroid dehydrogenase type 1: a role in restraining mast cell degranulation. PLoS ONE. 2013;8:e54640.
64. Coutinho AE, Gray M, Brownstein DG, et al. 11Beta-hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice. Endocrinology. 2012;153:234-40.
65. Chapman KE, Coutinho A, Gray M, Gilmour JS, Savill JS, Seckl JR. Local amplification of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 and its role in the inflammatory response. Ann N Y Acad Sci. 2006;1088:265-73.
66. Yau JLW, Noble J, Kenyon CJ, et al. Lack of tissue glucocorticoid reactivation in 11β-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc Natl Acad Sci USA. 2001;98:4716-21.
67. Sooy K, Webster SP, Noble J, et al. Partial deficiency or short-term inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves cognitive function in aging mice. J Neurosci. 2010;30:13867-72.
68. A study of R05093151 in patients with non-alcoholic fatty liver disease [ClinicalTrials.gov identifier NCT01277094]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov (Accessed 7 Feb 2013).